97231 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies; Hybrid immunoglobulins Igs containing Ig-regions, -domains or -residues form different species
Sub-classes:MICE THAT MAKE VL BINDING PROTEINS
#2NON-HUMAN ANIMALS HAVING AN ENGINEERED IMMUNOGLOBULIN LAMBDA LIGHT CHAIN AND USES THEREOF
#3ANTIBODY MOLECULES
#4HUMANIZED CHIMERIC BOVINE ANTIBODIES AND METHODS OF USE
#5MULTI-DOMAIN IMMUNOMODULATORY PROTEINS AND METHODS OF USE THEREOF
#6ANTIBODY MOLECULES
#7ICOS LIGAND VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF
#8ANTI-CD47 ANTIBODIES AND METHODS OF USE THEREOF
#9COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASE
#10METHODS AND COMPOSITIONS RELATING TO HIGH-THROUGHPUT MODELS FOR ANTIBODY DISCOVERY AND/OR OPTIMIZATION
#11COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASE
#12HUMAN LAMBDA LIGHT CHAIN MICE
#13ADAM6 MICE
#14ANTIBODY MOLECULES
#15METHOD FOR PREPARING TRANSGENIC NON-HUMAN ANIMAL HAVING GENOME INCLUDING HUMANIZED IMMUNOGLOBULIN GENE LOCUS
#16ANTI-TREM-1 ANTIBODIES
#17HUMAN IMMUNOGLOBULIN HEAVY CHAIN LONG CDR3 TRANSGENE CONSTRUCTS AND USES THEREOF
#18HUMANIZED NON-HUMAN ANIMALS WITH RESTRICTED IMMUNOGLOBULIN HEAVY CHAIN LOCI
#19ANTIBODY MOLECULES
#20Anti-sclerostin antibodies and methods of use
#21ANIMAL MODELS AND THERAPEUTIC MOLECULES
#22ANTIBODY MOLECULES
#23ANTI-C5A ANTIBODIES
#24Multi-domain immunomodulatory proteins and methods of use thereof
#25Antibodies specific for FLT3 and their uses
#26EXPRESS HUMANIZATION OF ANTIBODIES
#27BISPECIFIC ANTIBODIES TARGETING CD47 AND PD-L1 AND METHODS OF USE THEREOF
#28ANTIBODY MOLECULES
#29MODIFIED FC-REGIONS TO ENHANCE FUNCTIONAL AFFINITY OF ANTIBODIES AND ANTIGEN BINDING FRAGMENTS THEREOF
#30Transgenic Non-Human Vertebrate for the Expression of Class-Switched, Fully Human, Antibodies
#31MICE THAT MAKE VL BINDING PROTEINS
#32RESTRICTED IMMUNOGLOBULIN HEAVY CHAIN MICE
#33NON-HUMAN ANIMALS HAVING AN IMMUNOGLOBULIN HEAVY CHAIN VARIABLE REGION THAT INCLUDES AN ENGINEERED DIVERSITY CLUSTER AND USES THEREOF
#34MIXED BINDING DOMAINS
#35ANTIBODY MOLECULES
#36ANTIGEN-BINDING MOLECULES COMPRISING UNPAIRED VARIABLE DOMAINS
#37METHODS AND COMPOSITIONS RELATING TO ANTI-CHI3L1 ANTIBODY REAGENTS FOR THE TREATMENT OF FIBROSIS
#38NON-HUMAN ANIMALS HAVING AN ENGINEERED IMMUNOGLOBULIN LAMBDA LIGHT CHAIN AND USES THEREOF
#39METHODS AND COMPOSITIONS RELATING TO HIGH-THROUGHPUT MODELS FOR ANTIBODY DISCOVERY AND/OR OPTIMIZATION
#40Method for determining the in vivo interaction mode
#41Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation
#42ICOS ligand variant immunomodulatory proteins and uses thereof
#43MICE THAT MAKE VL BINDING PROTEINS
#44ADAM6 mice
#45ADAM6 mice
#46ANIMAL MODELS AND THERAPEUTIC MOLECULES
#47GENETIC ENGINEERING OF NON-HUMAN ANIMALS FOR THE PRODUCTION OF CHIMERIC ANTIBODIES
#48TRANSGENIC CHICKEN THAT PRODUCES HUMAN ANTIBODIES
#49Genetic engineering of non-human animals for the production of chimeric antibodies
#50GENETIC ENGINEERING OF NON-HUMAN ANIMALS FOR THE PRODUCTION OF CHIMERIC ANTIBODIES
#51Genetic engineering of non-human animals for the production of chimeric antibodies
#52Genetic engineering of non-human animals for the production of chimeric antibodies
#53Parathyroid hormone-anti-RANKL antibody fusion compounds
#54Cell culture methods
#55Humanized non-human animals with restricted immunoglobulin heavy chain loci
#56HUMAN LAMBDA LIGHT CHAIN MICE
#57Anti-HSV GB monoclonal antibody or antigen-binding fragment thereof
#58ANTIBODY MOLECULES
#59Method for preparing recombinant protein from bacterium and composition containing the same
#60Anti-C5A antibodies
#61Genetic engineering of non-human animals for the production of chimeric antibodies
#62Genetic engineering of non-human animals for the production of chimeric antibodies
#63Express humanization of antibodies
#64Humanized non-human animals with restricted immunoglobulin heavy chain loci
#65Method for treatment of an IL-17A-mediated disease through antibody administration specific to human IL-17A
#66USE OF HUMAN CELLS OF MYELOID LEUKAEMIA ORIGIN FOR EXPRESSION OF ANTIBODIES
#67METHODS OF TREATING DISEASES
#68Restricted immunoglobulin heavy chain mice
#69Antibodies with low immunogenicity and uses thereof
#70Mouse having an engineered immunoglobulin lambda light chain
#71Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
#72HUMAN LAMBDA LIGHT CHAIN MICE
#73Humanized non-human animals with restricted immunoglobulin heavy chain loci
#74HUMAN LAMBDA LIGHT CHAIN MICE
#75RODENTS HAVING AN ENGINEERED HEAVY CHAIN DIVERSITY REGION
#76METHOD FOR DETERMINING THE IN VIVO INTERACTION MODE
#77Antagonists of IL-6 to prevent or treat thrombosis
#78ADAM6 mice
#79ANTI-CD47 ANTIBODIES AND METHODS OF USE THEREOF
#80Antibodies specific for FLT3 and their uses
#81ADAM6 mice
#82ADAM6 mice
#83ADAM6 mice
#84METHODS OF TREATING DISEASES
#85Animal models and therapeutic molecules
#86ANTI-CD47 ANTIBODIES AND METHODS OF USE THEREOF
#87Anti-CD47 antibodies and methods of use thereof
#88Anti-C5a antibodies
#89CD40L binding polypeptide
#90P75NTR binding protein-Fc fusion protein and methods of treating pain
#91Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation
#92Human lambda light chain mice
#93METHODS OF TREATING DISEASES
#94ICOS ligand variant immunomodulatory proteins and uses thereof
#95RSPO BINDING AGENTS AND USES THEREOF
#96Anti-GD2 antibodies
#97Express humanization of antibodies
#98Mice that make Vbinding proteins
#99Genetic engineering of non-human animals for the production of chimeric antibodies
#100Velocity factor
#101Genetic engineering of non-human animals for the production of chimeric antibodies
#102Genetic engineering of non-human animals for the production of chimeric antibodies
#103Genetic engineering of non-human animals for the production of chimeric antibodies
#104Genetic engineering of non-human animals for the production of chimeric antibodies
#105Genetic engineering of non-human animals for the production of chimeric antibodies
#106Genetic engineering of non-human animals for the production of chimeric antibodies
#107Genetic engineering of non-human animals for the production of chimeric antibodies
#108Human lambda light chain mice
#109Animal models and therapeutic molecules
#110Anti-IL-17A Antibodies
#111Methods of producing anti-C5a antibodies
#112Hybrid constant regions
#113METHODS OF TREATING DISEASES
#114Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies
#115Methods of treating complement-associated disorders with anti-C5a antibodies
#116Anti-GD2 antibodies
#117Construction of diverse synthetic peptide and polypeptide libraries
#118Cyclic polypeptides for the treatment of heart failure
#119Sequence dependent aggregation
#120Human lambda light chain mice
#121Human lambda light chain mice
#122Anti-RSPO2 antibodies and uses thereof
#123Use of human cells of myeloid leukemia origin for expression of antibodies
#124Antagonists of IL-6 to prevent or treat thrombosis
#125Hybrid light chain mice
#126Hybrid light chain mice
#127Hybrid light chain mice
#128Methods of treating a tauopathy
#129ADAM6 mice
#130ADAM6 mice
#131Methods of treating complement-associated disorders with anti-C5a antibodies
#132Method of cloning a lambda light chain variable domain using a human lambda light chain mouse
#133Method of making antibodies using a human lambda light chain mouse
#134Method of making antibodies using a human lambda light chain mouse
#135Highly diverse combinatorial antibody libraries
#136Methods of reducing IL-6 activity for disease treatment
#137Human lambda light chain mice
#138Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
#139Humanized antibodies
#140Cyclic polypeptides for the treatment of heart failure
#141CANINISED ANTIBODIES AND METHOD FOR PRODUCTION OF SAME
#142Anti-CD47 antibodies and methods of use thereof
#143Velocity factor
#144Heterologous intron within an immunoglobulin domain
#145ADAM6 mice
#146Methods of generating libraries and uses thereof
#147TRANSGENIC AVES PRODUCING HUMAN POLYCLONAL ANTIBODIES
#148Hybrid light chain mice
#149Mice that make VL binding proteins
#150Methods of generating libraries and uses thereof
#151Dual variable region antibody-like binding proteins having cross-over binding region orientation
#152Dual variable region antibody-like binding proteins having cross-over binding region orientation
#153Humanized non-human animals with restricted immunoglobulin heavy chain loci
#154Human lambda light chain mice
#155Human lambda light chain mice
#156Express humanization of antibodies
#157Animal models and therapeutic molecules
#158Anti-C5a antibodies
#159Humaneered anti-factor B antibody
#160Anti-GD2 antibodies
#161CD3 IMMUNOTHERAPEUTICS AND USES THEREOF
#162Humanized antibodies targeting the EC1 domain of Cadherin-11 and related compositions and methods
#163Methods of inhibiting the interaction of C5aR with C5a with anti-C5aR antibodies
#164Insulin-like growth factor II (IGF-II) binding factors
#165Sequence dependent aggregation
#166Antagonists of IL-6 to prevent or treat thrombosis
#167ADAM6 mice
#168Antibody humanization by framework assembly
#169Humanized anti-C5aR antibodies
#170ANTIBODY MOLECULES THAT BIND TO IL-6 RECEPTOR
#171Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation
#172CH2 domain template molecules derived from rational grafting of donor loops onto CH2 scaffolds
#173Construction of diverse synthetic peptide and polypeptide libraries
#174Velocity factor
#175Design and construction of diverse synthetic peptide and polypeptide libraries
#176Mice that make VL binding proteins
#177Hybrid light chain mice
#178Human lambda light chain mice
#179SOMATIC HYPERMUTATION SYSTEMS
#180HUMANEERED ANTI-FACTOR B ANTIBODY
#181Methods of generating libraries and uses thereof
#182Transgenic Aves Producing Human Polyclonal Antibodies
#183Genetically modified non-human mammals and cells
#184Humanized anti-C5aR antibodies
#185SOMATIC HYPERMUTATION SYSTEMS
#186CD37 immunotherapeutics and uses thereof
#187Systems and methods for antibody engineering
#188Humanized antibodies
#189Antibody molecules that bind to IL-6 receptor
#190Methods of Humanizing and Affinity-Maturing Antibodies
#191Humanized immunoglobulin loci
#192METHODS AND COMPOSITIONS FOR PROLONGING ELIMINATION HALF-TIMES OF BIOACTIVE COMPOUNDS
#193Use of human cells of myeloid leukaemia origin for expression of antibodies
#194Insulin-like growth factor II (IGF-II) binding factors
#195Antagonists of IL-6 to prevent or treat thrombosis
#196CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
#197NOVEL RABBIT ANTIBODY HUMANIZATION METHODS AND HUMANIZED RABBIT ANTIBODIES
#198RECOMBINANT ANTI-CD4 ANTIBODIES FOR HUMAN THERAPY
#199RECOMBINANT ANTI-CD4 ANTIBODIES FOR HUMAN THERAPY
#200BINDING MOLECULES
#201Novel Rabbit Antibody Humanization Methods and Humanized Rabbit Antibodies
#202Methods of generating libraries and uses thereof
#203Construction of diverse synthetic peptide and polypeptide libraries
#204Somatic hypermutation systems
#205SINGLE DOMAIN LIGANDS, RECEPTORS COMPRISING SAID LIGANDS, METHODS FOR THEIR PRODUCTION AND USE OF SAID LIGANDS AND RECEPTORS
#206Humaneered anti-factor B antibody
#207Conjugate and its use as a standard in an immunoassay
#208Systems and Methods for Antibody Engineering
#209Methods and compositions for prolonging elimination half-times of bioactive compounds
#210Humanized antibody and process for preparing same
#211De-immunized streptokinase
#212Genetically modified non-human mammals and cells
#213Humanised antibodies
#214Humanised antibodies
#215Humanised antibodies
#216Humanized immunoglobulin loci
#217Transgenic aves producing human polyclonal antibodies
#218Humanised antibodies
#219Deimmunized binding molecules to CD3
#220Humanised antibodies
#221Humanised antibodies
#222Method for producing protein libraries and for selecting proteins from said libraries
#223Methods for humanizing rabbit monoclonal antibodies